Summary
GlobalData, the industry analysis specialist, has released a new report, "Type 1 Diabetes-Drug Pipeline Assessment and Market Forecasts to 2017". The report is an essential source of information and analysis on the global type 1 diabetes market. The report identifies the key trends shaping and driving the global type 1 diabetes market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the existing market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global type 1 diabetes sector. GlobalData estimates the global type 1 diabetes therapeutics market to have been valued at $2.7 billion in 2009. It is forecast to grow at 6.1% annually for the next seven years to reach $4.4 billion by 2017. This growth is primarily attributed to the increase in the average cost of therapy for type 1 diabetes and increases in the diseased and treatment seeking populations. The available treatment options are moderately successful in meeting the market demand leading to a moderate level of unmet need. A significant market potential exists to be exploited by any new entrant that will cater to the unmet needs for more convenient products with better efficacy and safety. GlobalData finds that the emerging therapies in the pipeline are expected to capture a small portion of the unmet need. The pipeline for type 1 diabetes appears to be moderately strong. Despite the high proportion of first-in-class drugs in the pipeline, the pipeline is not very strong as the development stage products are not likely to cater to the needs of all type 1 diabetes patients. While the pipeline products are not strong enough to impact the current market considerably, the success of these products will drive the market in the long run.

Table of Contents
1 Table of contents 3
1.1 List of Tables 5
1.2 List of Figures 5
2 Type 1 Diabetes Therapeutics Market: Market Characterization 6
2.1 Overview 6
2.2 Type 1 Diabetes Market Size 6
2.3 Type 1 Diabetes Therapeutics Market Forecast and CAGR 7
2.4 Drivers and Barriers for the Type 1 Diabetes Therapeutics Market 8
2.4.1 Drivers for the Type 1 Diabetes Therapeutics Market 8
2.4.2 Restraints for the Type 1 Diabetes Therapeutics Market 9
2.5 Opportunity and Unmet Need 10
2.6 Key Takeaway 11
3 Type 1 Diabetes Therapeutics Market: Competitive Assessment 12
3.1 Overview 12
3.2 Strategic Competitor Assessment 12
3.3 Product Profile for the Major Marketed Products in the Type 1 Diabetes Disease Market 13
3.3.1 Lantus (Insulin Glargine) 13
3.3.2 Humulin (Human Insulin) 16
3.3.3 Humalog (Insulin Lispro) 17
3.3.4 Novolog (Insulin Aspart) 19
3.3.5 Novolin (Human Insulin) 20
3.3.6 Apidra (Insulin Glulisine) 21
3.3.7 Levemir (Insulin Detemir) 23
3.4 Key Takeaway 25
4 Type 1 Diabetes Therapeutics Market: Pipeline Assessment 26
4.1 Overview 26
4.2 Strategic Pipeline Assessment 26
4.2.1 Technology Trends Analytic Framework 26
4.3 Type 1 Diabetes Therapeutics-Promising Drugs under Clinical Development 27
4.4 Molecule Profile for Promising Drugs under Clinical Development 28
4.4.1 rhGAD65 (Diamyd) 28
4.4.2 DiaPep277 28
4.4.3 Otelixizumab 29
4.4.4 Oral-lyn 30
4.5 Type 1 Diabetes Therapeutics Market-Clinical Pipeline by Mechanism of Action 31
4.6 Type 1 Diabetes Pipeline-Pipeline by Clinical Phases of Development 32
4.6.1 Type 1 Diabetes Therapeutics-Filed and Approved Drugs 32
4.6.2 Type 1 Diabetes Therapeutics-Phase III Clinical Pipeline 33
4.6.3 Type 1 Diabetes Therapeutics-Phase II Clinical Pipeline 33
4.6.4 Type 1 Diabetes Therapeutics-Phase I Clinical Pipeline 35
4.6.5 Type 1 Diabetes Therapeutics-Preclinical-Discovery Pipeline 35
4.7 Key Takeaway 36
5 Type 1 Diabetes Market: Implications for Future Market Competition 37
6 Type Diabetes Therapeutics Market: Future Players in the Type 1 Diabetes Therapeutics Market 39
6.1 Introduction 39
6.2 Novo Nordisk 39
6.2.1 Business Description 39
6.2.2 Metabolic Disorders Portfolio 40
6.2.3 Type 1 Diabetes Pipeline Portfolio 41
6.3 GlaxoSmithKline 42
6.3.1 Business Description 42
6.3.2 Metabolic Disorders Portfolio 43
6.3.3 Type 1 Diabetes Pipeline Portfolio 43
6.4 Eli Lilly 44
6.4.1 Business Description 44
6.4.2 Metabolic Disorders Portfolio 45
6.4.3 Type 1 Diabetes Pipeline Portfolio 45
6.5 Sanofi-Aventis 46
6.5.1 Business Description 46
6.5.2 Metabolic Disorders Portfolio 47
6.5.3 Type 1 Diabetes Pipeline Portfolio 47
7 Type 1 Diabetes Therapeutics Market: Appendix 48
7.1 Definitions 48
7.2 Scope of Pipeline Research 48
7.3 Abbreviations 48
7.4 Research Methodology 49
7.4.1 Coverage 50
7.4.2 Secondary Research 50
7.4.3 Forecasting 50
7.4.4 Primary Research 52
7.4.5 Expert Panel Validation 53
7.5 Contact Us 53
7.6 Disclaimer 53
7.7 Sources 54

List of Tables
1.1 List of Tables
Table 1: Type 1 Diabetes Therapeutics Market, Global, Revenues ($bn), 2001-2009 7
Table 2: Type 1 Diabetes Therapeutics Market, Global, Revenue Forecasts ($bn), 2009-2017 8
Table 3: Type 1 Diabetes Therapeutics Market, Lantus, Clinical Studies Outcome for Efficacy, 2010 14
Table 4:    Type 1 Diabetes Therapeutics Market, Lantus, Adverse Events in 28-Week Clinical Trials of Adults and Children With Type 1 Diabetes, 2010 14
Table 5: Type 1 Diabetes Therapeutics Market, Lantus, Clinical Studies Outcome for Safety, 2010 15
Table 6: Humulin-Glycemic Parameters at the End of Treatment Period in Randomized Patients in Three Months Cross-Over Studies for Type 1 Diabetes, 2010 16
Table 7: Humulin-Results of Three Month Cross-Over Studies Comparing Humulin with Humalog in Type 1 Diabetes, 2010 17
Table 8: Type 1 Diabetes Therapeutics Market, Humalog, Glycemic Parameters at the End of Treatment Period in Randomized Patients in Three Months Cross-Over Studies, 2010 18
Table 9: Humalog-Results of a Two Month Study Comparing the Use of Humalog and Humulin With Sulfonyluria (SU) Therapy, 2010 19
Table 10: Type 1 Diabetes Therapeutics Market, Novolog, Glycemic Parameters at the End of 24 Week Study, 2010 20
Table 11: Apidra-Efficacy Result of 26-Week Study Comparing Apidra with Insulin Lispro, 2010 22
Table 12: Apidra-Efficacy Result of 26-Week Study Comparing Apidra with Regular Insulin 22
Table 13: Apidra-Adverse Reactions Observed in Pooled Studies in Type 1 Diabetic Adults, 2010 22
Table 14: Levemir-Efficacy Result in 16-Week Non Blinded Study, 2010 23
Table 15:  Major Marketed Products Comparison in the Type 1 Diabetes Therapeutics Market,  2010 24
Table 16:  Type 1 Diabetes Therapeutics-Most Promising Drugs Under Clinical Development, 2010 27
Table 17: Type 1 Diabetes Therapeutics-Filed and Approved Drugs, 2010 32
Table 18: Type 1 Diabetes Therapeutics-Phase III Clinical Pipeline, 2010 33
Table 19: Type 1 Diabetes Therapeutics-Phase II Clinical Pipeline, 2010 33
Table 20: Type 1 Diabetes Therapeutics-Phase I Clinical Pipeline, 2010 35
Table 21: Type 1 Diabetes Therapeutics-Preclinical-Discovery Pipeline, 2010 35
Table 22:  Genzyme-Metabolic Disorders Marketed Products, 2010 40
Table 23: Novo Nordisk-Metabolic Disorders Pipeline Products, 2010 41
Table 24:  GlaxoSmithKline-Metabolic Disorders Marketed Products, 2010 43
Table 25: GlaxoSmithKline-Metabolic Disorders Pipeline Products, 2010 43
Table 26: Eli Lilly-Metabolic Disorders Marketed Products, 2010 45
Table 27: Eli Lilly-Metabolic Disorders Pipeline Products, 2010 45
Table 28: Sanofi-Aventis-Metabolic Disorders Marketed Products, 2010 47
Table 29: Sanofi-Aventis-Metabolic Disorders Pipeline Products, 2010 47

List of Figures
1.2 List of Figures
Figure 1: Type 1 Diabetes Therapeutics Market, Global, Revenues ($bn), 2001-2009 7
Figure 2: Type 1 Diabetes Therapeutics Market, Global, Revenue Forecasts ($bn), 2009-2017 8
Figure 3:  Opportunity and Unmet Need in the Type 1 Diabetes Therapeutics Market, 2010 10
Figure 4:   Strategic Competitor Assessment of the Major Marketed Products in Type 1 Diabetes Therapeutics, 2010 13
Figure 5:    Technology Trends Analytic Framework of the Type 1 Diabetes Therapeutics Pipeline, 2010 26
Figure 6:   Technology Trends Analytic Framework  of the Type 1 Diabetes Therapeutics
Pipeline-Description, 2010 27
Figure 7:  Type 1 Diabetes Therapeutics Market-Clinical Pipeline by Mechanism of Action, 2010 31
Figure 8:  Type 1 Diabetes Therapeutics Pipeline by Phase of Clinical Development, 2010 32
Figure 9:  Implications for Future Market Competition in the Type 1 Diabetes Market, 2010 37
Figure 10: Type 1 Diabetes Therapeutics Market-Clinical Pipeline by Company, 2010 39
Figure 11: GlobalData Methodology, 2010 49
Figure 12: GlobalData Market Forecasting Model, 2010 52